Render Target: SSR
Render Timestamp: 2024-11-21T20:17:19.498Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-20 06:18:51.394
Product last modified at: 2024-05-30T07:04:27.173Z
1% for the planet logo
PDP - Template Name: Growth Factors and Cytokines
PDP - Template ID: *******9ad1159

Human Transforming Growth Factor β3 (hTGF-β3) #8425

We recommend the following alternatives

Inquiry Info. # 8425

Please see our recommended alternatives.

    Product Information

    Product Usage Information

    Reconstitution:

    With carrier: Add sterile 20 mM Citrate, pH 3.0 to a final hTGF-β3 concentration of greater than 50 μg/ml. Solubilize for 30 minutes at room temperature with occasional gentle vortexing.

    Carrier free: Add sterile 20 mM Citrate, pH 3.0, or 20 mM Citrate, pH 3.0 containing protein to minimize absorption of hTGF-β3 to surfaces. Solubilize for 30 minutes at room temperature with occasional gentle vortexing. Stock hTGF-β3 should be greater than 50 μg/ml.

    Formulation

    With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM Citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hTGF-β3. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM Citrate, pH 3.0 containing 100 mM NaCl.

    Storage

    Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.
    Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

    Product Description

    MW (kDa) 12
    Purity >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hTGF-β3. Less than 5% migrates as monomer hTGF-β3 under non-reduced (-) conditions. All lots are greater than 98% pure.
    Endotoxin Less than 0.01 ng endotoxin/1 μg hTGF-β3.
    Activity The bioactivity of recombinant hTGF-β3 was determined by assessing inhibition of IL-4 induced HT-2 cell proliferation. The ED50 of each lot is between 0.02-0.1 ng/ml.
    Molecular Formula Recombinant hTGF-β3 contains no "tags" and the nonglycosylated protein has a calculated MW of 12,722. DTT-reduced protein migrates as a 12 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 22 kDa protein. The expected amino-terminal ALDTN of recombinant hTGF-β3 was verified by amino acid sequencing.

    Source / Purification

    Recombinant human TGF-β3 (hTGF-β3) Ala301-Ser412 (Accession #NP_003230) was expressed in human 293 cells at Cell Signaling Technology.

    Background

    TGF-β3 can induce cell proliferation and angiogenesis, and can promote some immune events while inhibiting others (1-3). TGF-β3 is produced by chondrocytes, glial cells, astrocytes and some cancer cells (3,4). TGF-β3 binds to TβRII homodimer, which then complexes with TβRI homodimer (1,5). The oligomeric receptor complex phosphorylates subsets of SMAD proteins that then act to induce or suppress target genes (1,5). Based on knock-out studies in mice, TGF-β3 is critical for lung and palate development (6).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.